A recent high-level panel discussion, convened by the Technology Academy Finland (TAF) and hosted at the residence of the Finnish Ambassador to the UK, brought together luminaries from the biotech sector, including previous winners of the prestigious Millennium Technology Prize, to dissect the intricacies of the European biotech landscape. The dialogue offered invaluable insights and strategic counsel for both established companies and nascent start-ups navigating the complex journey from scientific discovery to market impact. The overarching theme that emerged underscored Europe’s formidable strength in generating groundbreaking scientific ideas but also highlighted a persistent challenge in retaining and commercializing these innovations on the continent, often seeing significant intellectual property and economic value migrate across the Atlantic to larger, more commercially adept US companies.
The Millennium Technology Prize: A Catalyst for Global Innovation
At the heart of this insightful gathering was the Millennium Technology Prize, often referred to as Finland’s answer to the Nobel Prizes. Administered by the Technology Academy Finland (TAF) in Helsinki, this biennial €1 million award celebrates technological innovations that demonstrably "promote the well-being of people and the planet." More than merely a recognition of past achievements, the prize, according to TAF CEO Maija Liiri, is designed "not only to recognize impact, but also to create it." This proactive mission drives TAF’s ambitious strategy to globalize the prize’s reach and influence. Liiri highlighted the recent partnership with Nanyang Technological University (Singapore) as a testament to this global vision, with the UK identified as the next strategic target for a university collaboration, aiming to extend the prize’s unique blend of recognition and catalytic dialogue to academic hubs worldwide.
The Millennium Technology Prize has a rich history of honouring transformative breakthroughs. Past laureates include Sir Tim Berners-Lee for the World Wide Web, Shinya Yamanaka for induced pluripotent stem cells, and Stuart Parkin for his work on spintronic technologies that revolutionized data storage. These examples underscore the prize’s commitment to recognizing innovations with profound societal benefits, a principle that continues to guide its selection process and outreach initiatives.
A Distinguished Panel Convenes in London
The panel discussion itself was a significant event, hosted in the diplomatic setting of the Finnish Ambassador to the UK’s residence. The distinguished lineup featured the joint winners of the 2020 Millennium Technology Prize: Professor David Klenerman and Professor Shankar Balasubramanian, both esteemed researchers from the University of Cambridge, UK. Their pioneering work on sequencing by synthesis revolutionized DNA sequencing, drastically accelerating the pace of genomic research and plummeting associated costs. This breakthrough has been instrumental in advancing personalized medicine, disease diagnostics, and our fundamental understanding of life itself.
Joining the laureates were two prominent figures from the European health and biotechnology sector: Charles Alessi, Chief Clinical Officer at Nightingale Health (Helsinki, Finland), a company at the forefront of preventative health insights, and Becky Warnes, Public Affairs and NHS Liaison Manager for Orion Pharma (Espoo, Finland), representing their recently established R&D site in Cambridge, UK. The diversity of perspectives, spanning fundamental research, prize-winning innovation, and commercial biotech leadership, enriched the dialogue significantly.
In his opening remarks, the Finnish Ambassador to the UK, Teemu Turunen, set a crucial tone for the discussion. He observed that while the UK, Finland, and indeed Europe at large, serve as fertile ground for generating innovative ideas, there’s a discernible pattern where these innovations, once matured, are frequently commercialized or scaled by larger, often US-based, entities. This trend often results in the bulk of the generated revenue sailing across the Atlantic, posing a strategic economic challenge for European nations keen to foster and retain their homegrown technological prowess. This issue became a recurring motif throughout the panel, prompting a deep dive into the underlying factors and potential solutions.
Key Learnings for Biotech Entrepreneurs: Navigating the European Landscape
The panel meticulously explored a series of critical factors for success in establishing and growing new biotech ventures within Europe, while simultaneously addressing the systemic challenges that often impede their progress. The discussion offered a valuable exchange of insights between the UK and Finnish ecosystems, highlighting complementary strengths and areas for mutual learning. The following are the principal takeaways from this illuminating event.
1. Cultivating a Permissive and Collaborative Ecosystem for Innovation
A foundational principle emphasized by the panelists for fostering technological breakthroughs was the creation of a "permissive environment." Charles Alessi articulated this eloquently, suggesting that whether within a university department or a corporate R&D lab, such an environment must actively encourage freedom of thought, action, and even unorthodox approaches. This latitude is crucial for allowing curious, free-thinking minds the necessary space to conceive and develop novel ideas without undue constraints.
Professor Balasubramanian reinforced this by advocating for the nurturing of curiosity and intellectual freedom within educational systems, stressing that these vital attributes should not be stifled as students transition into higher education and professional research. An environment that embraces intellectual exploration from an early stage is more likely to produce individuals capable of radical innovation.
This permissiveness, the panelists agreed, must be combined with a culture of collaboration rather than cutthroat competition. Professor Klenerman championed a team-oriented approach where individuals pull together to refine and solidify nascent ideas into well-formed concepts. This collaborative spirit, contrasted with isolated competitive efforts, ensures that bold ideas are also rigorously vetted and informed by diverse perspectives, leading to more robust and impactful innovations. Empirical studies on innovation ecosystems consistently show that environments characterized by open communication, cross-disciplinary collaboration, and psychological safety are significantly more productive in generating novel solutions and fostering breakthrough technologies.
2. Embracing Risk: The Indispensable Role of Failure and Societal Mindset
A truly permissive environment, the panel argued, extends beyond merely accepting free thought; it necessitates an acceptance of failure. Professor Balasubramanian candidly highlighted the reality that a vast majority of ideas emerging from creative environments will not translate into practical applications or achieve sufficient impact to be viable. Crucially, the viability of an idea is often not apparent until significant resources have been invested. These perceived "failures," however, must be reframed as essential byproducts of a creative process, serving as invaluable sources of learning from which to pivot quickly to the next promising idea. The biotech sector, with its inherently high-risk, high-reward nature, exemplifies this truth, where clinical trial failure rates can exceed 90% for certain drug classes.
The broader societal attitude towards risk was further explored by Becky Warnes, particularly in the context of governmental policy. Warnes pointed out that many factors critical to biotech success are influenced at a national level by government decisions. This creates a dilemma, as politicians operate under constant public scrutiny and the ever-present threat of election cycles. In societies like the UK, where there is often a public demand for a "zero-risk" environment, governmental risk appetite tends to be low. This cautious approach has cascading effects on the biotech industry, potentially limiting the public funding and supportive policies necessary to underwrite a multitude of creative, yet inherently risky, ideas. Warnes posited that for the requisite capital and infrastructure to support a vibrant innovation pipeline, "we need to be more accepting of risk as a society." This sentiment echoes calls from various European innovation bodies for a cultural shift towards greater risk tolerance, mirroring the more adventurous venture capital landscape found in regions like Silicon Valley.
3. Strategic Location: The ‘Where’ and ‘How’ of Commercialization
For entrepreneurs looking to commercialize an idea, the strategic choice of location and operational structure is paramount. Klenerman and Balasubramanian’s journey with sequencing by synthesis offers a prime example. They recognized early on that while their idea was revolutionary, its potential would remain unrealized if they couldn’t develop it in an environment conducive to scaling and eventual transfer to a larger entity. They determined that the university, despite being the birthplace of the idea, was not the practical setting for this commercial development. This led them to establish Solexa, a dedicated company focused entirely on developing the technology. As Klenerman explained, Solexa was a "hugely technical company, solely focused on developing the technology before looking to find a larger company to take the technology and distribute it around the world."
This strategic decision proved highly successful. In 2007, Solexa was acquired by Illumina (CA, USA), a global leader in sequencing technology. At the time, no existing European sequencing company possessed the necessary investment capacity or global infrastructure to fully realize Solexa’s potential. Illumina’s bid ultimately prevailed over competitors like Applied Biosystems (now part of Thermo Fisher Scientific; MA, USA) and the more diagnostics-focused Roche (Basel, Switzerland), primarily due to Illumina’s more aligned and inspiring vision for the company’s future. This transaction, while a commercial success for the founders, starkly illustrates the challenge Europe faces in scaling its own innovations to global prominence.
For tech entrepreneurs who aspire to keep their companies rooted locally, Klenerman’s advice was pragmatic: actively engage with and learn from others in your region who have successfully commercialized innovations. Critical questions include: What local support structures are available? What specific lessons did they learn? And, in hindsight, what might they have done differently? While direct applicability to every project may vary, these insights can offer invaluable guidance, inform strategic decisions, or even prompt the realization that relocation might be necessary to access the optimal ecosystem.
4. Navigating the Commercial Landscape: Leveraging Ecosystem Strengths
Understanding and leveraging the nuances of the national commercial landscape is crucial for a biotech company’s trajectory. Orion Pharma’s decision to expand its UK R&D operations into Cambridge exemplifies this. Identifying Cambridge as "the home of biologics in the UK" provided a strategic advantage, particularly in talent acquisition. The company was able to recruit many skilled individuals who had been made redundant from another business vacating the same site. This strategic location, combined with a methodical expansion approach, contributed to a highly successful venture for the Finnish pharmaceutical giant.
Becky Warnes elaborated on the complementary strengths of the UK and Finnish ecosystems. She highlighted the UK’s excellence in fundamental research, producing a wealth of talent from its university system. Finland, by contrast, offers a robust counterpart with a stronger data focus, adept at converting early-stage research into commercial products, establishing safety profiles, and refining manufacturing procedures. This dynamic illustrates the significant value in playing to the distinct strengths of different national ecosystems within Europe.
The commercial landscape of a country profoundly influences the operational "pain points" for a startup. Finland’s smaller domestic market, for instance, might initially appear as a limitation, potentially reducing interest from international investors. However, the country compensates with a strong national focus on biotech. Business Finland provides substantial support for internationalization, actively assisting businesses in expanding into larger global markets. Furthermore, Finland boasts a healthy, internally focused venture capital funding culture, partly bolstered by government funding that helps de-risk later stages of company development.
In contrast, the UK Research and Innovation (UKRI) framework offers significant early-stage support, with its commercialization arm, Innovate UK, providing continuous assistance throughout the commercialization process. This makes the UK a hotbed for new ideas. However, the emphasis on internationalization and securing the substantial funds needed for global scaling often requires UK companies to look towards international investment, underscoring a different set of challenges and opportunities.
5. The Entrepreneurial Imperative: Belief and Unwavering Commitment
Ultimately, a consensus emerged among all panelists regarding the paramount importance of profound belief in one’s idea and an unwavering commitment to its pursuit before embarking on commercialization. Entrepreneurs must be prepared to dedicate not just years, but often decades, to their vision. The journey from the initial conception of sequencing by synthesis to Solexa’s eventual sale to Illumina spanned a decade – a timeline Klenerman considered "fairly speedy" in the grand scheme of deep tech innovation.
Professor Balasubramanian further underscored this point by revealing his long-term engagement with other companies he had co-founded, one for 18 years and another for 12 years. He firmly believes this commitment runs counter to a prevalent theory that ideas should be established and then quickly handed over to another group for commercialization. Balasubramanian argued that this "establish and hand over" approach is often flawed, frequently leading to disappointment and difficulties in securing sustained investment. He articulated this with a compelling rhetorical question: "If you don’t believe in your idea enough to invest your own time in it, why should anyone else?" This statement encapsulates the core entrepreneurial spirit required to navigate the arduous path of biotech innovation, emphasizing that personal conviction and enduring dedication are non-negotiable prerequisites for success.
Broader Implications and the Future of European Biotech
The panel discussion provided a comprehensive, fact-based analysis of the European biotech ecosystem, moving beyond anecdotal observations to identify systemic strengths and weaknesses. The insights gleaned from the Millennium Technology Prize laureates and industry leaders underscore a critical juncture for European innovation. While the continent excels in foundational research and intellectual output, bridging the "valley of death" between discovery and large-scale commercialization remains a significant hurdle.
The discussion implicitly highlighted several areas for strategic focus: fostering a greater societal and governmental appetite for risk, enhancing cross-border collaboration and investment mechanisms within Europe, streamlining regulatory pathways, and actively promoting a culture of long-term entrepreneurial commitment. Initiatives like the Millennium Technology Prize, by fostering such high-level dialogues and connecting diverse stakeholders, play a crucial role in shaping policy, encouraging investment, and inspiring the next generation of innovators. By learning from each other’s ecosystems and collectively addressing the challenges, Europe has the potential to not only generate world-changing innovations but also to retain and commercialize them on a global scale, fulfilling the prize’s mission of promoting well-being for people and the planet.
The next Millennium Technology Prize will be awarded in June 2027 in Helsinki, Finland, continuing its tradition of celebrating and catalysing transformative technological advancements. Readers are also encouraged to look out for an upcoming in-depth interview with David Klenerman, which will delve further into their remarkable journey and the pivotal factors behind their groundbreaking scientific and commercial achievements.
Leave a Reply